Patients' experiences of cancer immunotherapy with immune checkpoint inhibitors: A systematic review and thematic synthesis.

Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 9207302 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2702 (Electronic) Linking ISSN: 09621067 NLM ISO Abbreviation: J Clin Nurs Subsets: MEDLINE

Original Publication: Oxford ; Boston : Blackwell Scientific Publications, c1992-

Neoplasms*/drug therapy ; Neoplasms*/psychology ; Immune Checkpoint Inhibitors*/therapeutic use ; Immune Checkpoint Inhibitors*/pharmacology ; Immunotherapy*/methods; Humans ; Qualitative Research ; Female ; Male

Aim: To obtain a deeper understanding of peoples' experiences of cancer treatments with immune checkpoint inhibitors (ICIs).
Background: ICIs are transforming survival outcomes for many with certain advanced cancers. Given the possibility of unique immune-related adverse events (irAEs), understanding treatment experiences is crucial to identify support needs and provide safe and effective person-centred care.
Design: A systematic review of qualitative research and thematic synthesis. To report this review, the Preferred Reporting Items for Systematic Analysis and Meta Analysis (PRISMA) checklist and Enhancing Transparency in Reporting the Synthesis of Qualitative Research (ENTREQ) guidance have been used.
Data Sources: MEDLINE, EMBASE, PsycINFO, CINAHL and Web of Science databases were searched in January 2022 for eligible studies published in English from database inception.
Review Methods: Two reviewers independently screened records, identified papers for inclusion and appraised methodological quality using the Critical Appraisal Skills Programme checklist. Themes were developed using thematic synthesis.
Results: Eighteen papers were included and three analytical themes developed: immune checkpoint inhibitor treatment decision-making; the experience and impact of immune checkpoint inhibitor treatments; and appraising and responding to irAEs.
Conclusion: The synthesis renders visible individuals' unmet information, psychological and practical support needs. It identifies shortcomings in immune checkpoint inhibitor treatment decision-making processes and highlights the need for healthcare professionals to recognise and sensitively handle individuals' treatment expectations. Individuals' understandings of and responses to irAEs are also illustrated, and attention drawn to patients' concerns about healthcare professionals' checkpoint inhibitor and irAEs knowledge.
Implications for Patient Care: To sensitively manage treatment expectations and uncertainties, and optimise health outcomes, there are distinct points in treatment trajectories where care and support might require adapting and enhancing.
Impact: This review addresses people's experiences of immune checkpoint inhibitor treatments. The core findings reveal unmet information, psychological and practical support needs. Insights derived from this review will enhance individuals' experiences and outcomes and healthcare professionals' practice.
Patient or Public Contribution: No patient or public involvement.
(© 2024 The Authors. Journal of Clinical Nursing published by John Wiley & Sons Ltd.)

Ala‐Leppilampi, K., Baker, N. A., McKillop, C., Butler, M. O., Siu, L. L., Spreafico, A., … Hansen, A. R. (2020). Cancer patients' experiences with immune checkpoint modulators: A qualitative study. Cancer Medicine, 9(9), 3015–3022. https://doi.org/10.1002/cam4.2940.
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y. C., Karapetis, C. S., Hiret, S., & Ostoros, G. (2018). Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. New England Journal of Medicine, 379, 2342–2350. https://doi.org/10.1056/NEJMoa1809697.
Ascierto, P. A., Long, G. V., Robert, C., Brady, B., Dutriaux, C., Di Giacomo, A. M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka‐Warzocha, E., Savage, K. J., Hernberg, M. M., Lebbé, C., Charles, J., Mihalcioiu, C., Chiarion‐Sileni, V., Mauch, C., Cognetti, F., & Ny, L. (2019). Survival outcomes in patients with previously untreated BRAF wild‐type advanced melanoma treated with nivolumab therapy. Journal of the American Medical Association Oncology, 5(2), 187–194. https://doi.org/10.1001/jamaoncol.2018.4514.
Asher, N., Marom, E. M., Ben‐Betzalel, G., Baruch, E. N., Steinberg‐Silman, Y., Schachter, J., Shapira‐Frommer, R., & Markel, G. (2019). Recurrent pneumonitis in patients with melanoma treated with immune checkpoint inhibitors. The Oncologist, 24(5), 640–647. https://doi.org/10.1634/theoncologist.2018‐0352.
Bagchi, S., Yuan, R., & Engleman, E. G. (2021). Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance. Annual Review of Pathology, 16, 223–249. https://doi.org/10.1146/annurev‐pathol‐042020‐042741.
Bharmal, M., Marrel, A., Hennessy, M., Fofana, F., Lambert, J., & Arnould, B. (2018). Comparative effectiveness of avelumab versus chemotherapy in Merkel cell carcinoma: Innovative use of patient insights. Journal of Comparative Effectiveness Research, 7(9), 881–890. https://doi.org/10.2217/cer‐2018‐0048.
Booth, A. (2016). Searching for qualitative research for inclusion in systematic reviews: A structured methodological review. Systematic Reviews, 5(1), 74. https://doi.org/10.1186/s13643‐016‐0249‐x.
Booth, A., Noyes, J., Flemming, K., Gerhardus, A., Wahlster, P., van der Wilt, G. J., Mozygemba, K., Refolo, P., Sacchini, D., Tummers, M., & Rehfuess, E. (2018). Structured methodology review identified seven (RETREAT) criteria for selecting qualitative evidence synthesis approaches. Journal of Clinical Epidemiology, 99, 41–52. https://doi.org/10.1016/j.jclinepi.2018.03.003.
Brom, L., De Snoo‐Trimp, J. C., Onwuteaka‐Philipsen, B. D., Widdershoven, G. A., Stiggelbout, A. M., & Pasman, H. R. (2017). Challenges in shared decision making in advanced cancer care: A qualitative longitudinal observational and interview study. Health Expectations, 20(1), 69–84. https://doi.org/10.1111/hex.12434.
Cappelli, L. C., Grieb, S. M., Shah, A. A., Bingham, C. O., 3rd, & Orbai, A. M. (2020). Immune checkpoint inhibitor‐induced inflammatory arthritis: A qualitative study identifying unmet patient needs and care gaps. BMC Rheumatology, 4, 32. https://doi.org/10.1186/s41927‐020‐00133‐8.
Centre for Reviews and Dissemination. (2009). Systematic reviews: CRD's guidance for undertaking reviews in health care. University of York.
Cheung, W. Y., White, M. K., Bayliss, M. S., Stroupe, A., Lovley, A., King‐Kallimanis, B. L., & Lasch, K. (2019). Patient‐reported treatment‐related symptom burden for patients with advanced melanoma in Canada. Supportive Care in Cancer, 27(1), 219–227. https://doi.org/10.1007/s00520‐018‐4316‐9.
Critical Appraisal Skills Programme. (2019). CASP qualitative studies checklist. Retrieved from: https://casp‐uk.net/casp‐tools‐checklists/.
Harrington, K. J., Ferris, R. L., Blumenschein, G., Colevas, A. D., Fayette, J., Licitra, L., Kasper, S., Even, C., Vokes, E. E., Worden, F., Saba, N. F., Kiyota, N., Haddad, R., Tahara, M., Grünwald, V., Shaw, J. W., Monga, M., Lynch, M., Taylor, F., & DeRosa, M. (2017). Nivolumab versus standard, single‐agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (check mate 141): Health‐related quality‐of‐life results from a randomised, phase 3 trial. Lancet Oncology, 18(8), 1104–1115. https://doi.org/10.1016/S1470‐2045(17)30421‐7.
Hou, Y., Hou, Y., Li, J., Yu, L., & Yan, L. (2023). A qualitative research exploring the experiences of patients receiving immune checkpoint inhibitors for advanced lung cancer. Supportive Care in Cancer, 31(8), 498. https://doi.org/10.1007/s00520‐023‐07965‐3.
Hyatt, A., Morkunas, B., Davey, D., Thai, A. A., Trewhella, M., Duffy, M., Dawson, T., Gourlay, P., Hutchison, J., & Milne, D. (2021). Co‐design and development of online video resources about immunotherapy with patients and their family. Patient Education and Counselling, 104(2), 290–297. https://doi.org/10.1016/j.pec.2020.09.014.
Ihrig, A., Richter, J., Grullich, C., Apostolidis, L., Horak, P., Villalobos, M., Grapp, M., Friederich, H. C., & Maatouk, I. (2020). Patient expectations are better for immunotherapy than traditional chemotherapy for cancer. Journal of Cancer Research and Clinical Oncology, 146(12), 3189–3198. https://doi.org/10.1007/s00432‐020‐03336‐1.
Jamieson, L., Forster, M. D., Zaki, K., Mithra, S., Alli, H., O'Connor, A., Patel, A., Wong, I. C. K., & Chambers, P. (2020). Immunotherapy and associated immune‐related adverse events at a large UK centre: A mixed methods study. BMC Cancer, 20(1), 743. https://doi.org/10.1186/s12885‐020‐07215‐3.
Khalid, A. B., Calderon, G., Jalal, S. I., & Durm, G. A. (2022). Physician awareness of immune‐related adverse events of immune checkpoint inhibitors. Journal of the National Comprehensive Cancer Network, 20(12), 1316–1320. https://doi.org/10.6004/jnccn.2022.7064.
Lai‐Kwon, J., Heynemann, S., Flore, J., Dhillon, H., Duffy, M., Burke, J., Briggs, L., Leigh, L., Mileshkin, L., Solomon, B., Ball, D., Kokanovic, R., & Jefford, M. (2021). Living with and beyond metastatic non‐small cell lung cancer: The survivorship experience for people treated with immunotherapy or targeted therapy. Journal of Cancer Survivorship, 15(3), 392–397. https://doi.org/10.1007/s11764‐021‐01024‐8.
Lambert, J., Marrel, A., D'Angelo, S. P., Burgess, M. A., Chmielowski, B., Fazio, N., Gambichler, T., Grob, J. J., Lebbé, C., Robert, C., Russell, J., Güzel, G., & Bharmal, M. (2020). Patient experiences with Avelumab in treatment‐naive metastatic Merkel cell carcinoma: Longitudinal qualitative interview findings from JAVELIN Merkel 200, a Registrational clinical trial. The Patient, 13(4), 457–467. https://doi.org/10.1007/s40271‐020‐00428‐5.
Larkin, J., Chiarion‐Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Lao, C. D., Cowey, C. L., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hogg, D., Hill, A., Márquez‐Rodas, I., Haanen, J., Guidoboni, M., Maio, M., Schöffski, P., … Wolchok, J. D. (2019). Five‐year survival with combined Nivolumab and Ipilimumab in advanced melanoma. New England Journal of Medicine, 381(16), 1535–1546. https://doi.org/10.1056/nejmoa1910836.
Lehmann, V., Labrie, N., van Weert, J., van Dulmen, S., de Haes, H., Kersten, M. J., Pieterse, A. H., & Smets, E. (2020). Tailoring the amount of treatment information to cancer patients' and survivors' preferences: Effects on patient‐reported outcomes. Patient Education and Counselling, 103(3), 514–520. https://doi.org/10.1016/j.pec.2019.09.024.
Levy, D., Dhillon, H. M., Lomax, A., Marthick, M., McNeil, C., Kao, S., & Lacey, J. (2019). Certainty within uncertainty: A qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy. Supportive Care in Cancer, 27(5), 1845–1852. https://doi.org/10.1007/s00520‐018‐4443‐3.
Livingstone, A., Agarwal, A., Stockler, M. R., Menzies, A. M., Howard, K., & Morton, R. L. (2020). Preferences for immunotherapy in melanoma: A systematic review. Annals of Surgical Oncology, 27(2), 571–584. https://doi.org/10.1245/s10434‐019‐07963‐y.
Livingstone, A., Milne, D., Dempsey, K., Muscat, D. M., Menzies, A. M., Howard, K., Stockler, M. R., & Morton, R. L. (2021). Should I have adjuvant immunotherapy? An interview study among adults with resected stage 3 melanoma and their partners. The Patient, 14(5), 635–647. https://doi.org/10.1007/s40271‐021‐00507‐1.
Lobb, E., Lacey, J., Kearsley, J., Liauw, W., White, L., & Hosie, A. (2015). Living with advanced cancer and an uncertain disease trajectory: An emerging patient population in palliative care? BMJ Supportive and Palliatiative Care, 5(4), 352–357. https://doi.org/10.1136/bmjspcare‐2012‐000381.
Methley, A. M., Campbell, S., Chew‐Graham, C., McNally, R., & Cheraghi‐Sohi, S. (2014). PICO, PICOS and SPIDER: A comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Services Research, 14(1), 579. https://doi.org/10.1186/s12913‐014‐0579‐0.
Milne, D., Hyatt, A., Billett, A., Gough, K., & Krishnasamy, M. (2020). Exploring the experiences of people treated with immunotherapies for advanced melanoma and those caring for them: "Real‐world" data. Cancer Nursing, 43(2), E97–E104. https://doi.org/10.1097/NCC.0000000000000683.
Mok, T. S. K., Wu, Y. L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Jr., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., Kubota, K., Lubiniecki, G. M., Zhang, J., Kush, D., Lopes, G., & KEYNOTE‐042 Investigators. (2019). Pembrolizumab versus chemotherapy for previously untreated, PD‐L1‐expressing, locally advanced or metastatic non‐small‐cell lung cancer (KEYNOTE‐042): A randomised, open‐label, controlled, phase 3 trial. Lancet, 393(10183), 1819–1830. https://doi.org/10.1016/S0140‐6736(18)32409‐7.
Munn, Z., Stern, C., Aromataris, E., Lockwood, C., & Jordan, Z. (2018). What kind of systematic review should I conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences. BMC Medical Research Methodology, 18(1), 5. https://doi.org/10.1186/s12874‐017‐0468‐4.
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo‐Wilson, E., McDonald, S., … Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71.
Park, R., Shaw, J. W., Korn, A., & McAuliffe, J. (2020). The value of immunotherapy for survivors of stage IV non‐small cell lung cancer: Patient perspectives on quality of life. Journal of Cancer Survivorship: Research and Practice, 14(3), 363–376. https://doi.org/10.1007/s11764‐020‐00853‐3.
Petrella, T. M., Robert, C., Richtig, E., Miller, W. H., Jr., Masucci, G. V., Walpole, E., Lebbe, C., Steven, N., Middleton, M. R., Hille, D., Zhou, W., Ibrahim, N., & Cebon, J. (2017). Patient‐reported outcomes in KEYNOTE‐006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma. European Journal of Cancer, 86, 115–124. https://doi.org/10.1016/j.ejca.2017.08.032.
Petrillo, L. A., Traeger, L. N., Sommer, R. K., Zhou, A. Z., Temel, J. S., & Greer, J. A. (2021). Experience and supportive care needs of metastatic lung cancer survivors living with uncertainty: A brief qualitative report. Journal of Cancer Survivorship, 15(3), 386–391. https://doi.org/10.1007/s11764‐021‐.
Ramos‐Casals, M., Brahmer, J., Callahan, M. K., Flores‐Chávez, A., Keegan, N., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suárez‐Almazor, M. E. (2020). Immune‐related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers, 6(38), 1–21. https://doi.org/10.1038/s41572‐020‐0160‐6.
Rodenbach, R. A., Althouse, A. D., Schenker, Y., Smith, T. J., Chu, E., White, D. B., Bakitas, M., & Arnold, R. M. (2021). Relationships between advanced cancer Patients' worry about dying and illness understanding, treatment preferences, and advance care planning. Journal of Pain and Symptom Management, 61(4), 723–731.e1. https://doi.org/10.1016/j.jpainsymman.2020.09.004.
Schadendorf, D., Larkin, J., Wolchok, J., Hodi, F. S., Chiarion‐Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J. J., Cowey, C. L., Lao, C., Wagstaff, J., Callahan, M. K., Postow, M. A., Smylie, M., Ferrucci, P. F., Dummer, R., Hill, A., Taylor, F., Sabater, J., & Walker, D. (2017). Health‐related quality of life results from the phase III check mate 067 study. European Journal of Cancer, 82, 80–91. https://doi.org/10.1016/j.ejca.2017.05.031.
Shilling, V., Starkings, R., Jenkins, V., & Fallowfield, L. (2017). The pervasive nature of uncertainty‐a qualitative study of patients with advanced cancer and their informal caregivers. Journal of Cancer Survivorship, 11(5), 590–603. https://doi.org/10.1007/s11764‐017‐0628‐x.
Shuk, E., Shoushtari, A. N., Luke, J., Postow, M. A., Callahan, M., Harding, J. J., Roth, K. G., Flavin, M., Granobles, A., Christian, J., Gold, G., Schoenhammer, M., Gordon, M., Cimaglia, N., Dyson, R., Goodman‐Davis, N., Colgan, M. N., Jefferson, I. S., Munhoz, R., … Hay, J. L. (2017). Patient perspectives on ipilimumab across the melanoma treatment trajectory. Supportive Care in Cancer, 25(7), 2155–2167. https://doi.org/10.1007/s00520‐017‐3621‐z.
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022). Cancer statistics, 2022. CA: A Cancer Journal for Clinicians, 1, 7–33. https://doi.org/10.3322/caac.21708.doi:10.3322/caac.21708.
Tarbi, E. C., & Pirl, W. F. (2022). Sharing decisions about systemic therapy for advanced cancers. JCO Oncology Practice, 18(8), 543–544. https://doi.org/10.1200/OP.21.00804.
Thomas, J., & Harden, A. (2008). Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Medical Research Methodology, 8(1), 45. https://doi.org/10.1186/1471‐2288‐8‐45.
Thomas, J., O'Mara‐Eves, A., Harden, A., & Newman, M. (2017). Chapter 8: Synthesis methods for combining and configuring textual or mixed methods data. In An Introduction to systematic reviews (pp. 181–209). Sage.
Thorne, S., Oliffe, J. L., & Stajduhar, K. I. (2013). Communicating shared decision‐making: Cancer patient perspectives. Patient Education and Counselling, 90(3), 291–296. https://doi.org/10.1016/j.pec.2012.02.018.
Tong, A., Flemming, K., McInnes, E., Oliver, S., & Craig, J. (2012). Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Medical Research Methodology, 12, 181. https://doi.org/10.1186/1471‐2288‐12‐181.
Wang, D. Y., Salem, J.‐E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., Rathmell, W. K., Ancell, K. K., Balko, J. M., Bowman, C., Davis, E. J., Chism, D. D., Horn, L., Long, G. V., Carlino, M. S., … Johnson, D. (2018). Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta‐analysis. JAMA Oncology, 4(12), 1721–1728.
Wasp, G., Knutzen, K., Murray, G., Brody‐Bizar, O. C., Liu, M. A., Pollak, K. I., Tulsky, J. A., Schenker, Y., & Barnato, A. E. (2022). Systemic therapy decision making in advanced cancer: A qualitative analysis of patient‐oncologist encounters. JCO Oncology Practice, 18(8), e1357–e1366. https://doi.org/10.1200/OP.21.00377.
Watts, T., & Bower, J. (2019). Still lost in transition: A qualitative descriptive study of people's experiences following treatment completion for haematological cancer in Wales, UK. E cancer Medical Science, 13, 985. https://doi.org/10.3332/ecancer.2019.985.
Wong, A., Billett, A., & Milne, D. (2019). Balancing the hype with reality: What do patients with advanced melanoma consider when making the decision to have immunotherapy? The Oncologist, 24(11), e1190–e1196. https://doi.org/10.1634/theoncologist.2018‐0820.
Xie, Q., Sun, C., Fei, Z., & Yang, X. (2022). Accepting immunotherapy after multiline treatment failure: An exploration of the anxiety and depression in patients with advanced cancer experience. Patient Preference and Adherence, 16, 1–9. https://doi.org/10.2147/PPA.S346171.
Younger, E., Jones, R., den Hollander, D., Soomers, V., Desar, I., Benson, C., Young, R., Oosten, A., de Haan, J., Miah, A., Zaidi, S., Gelderblom, H., Steeghs, N., Husson, O., & van der Graaf, W. (2021). Priorities and preferences of advanced soft tissue sarcoma patients starting palliative chemotherapy: Baseline results from the HOLISTIC study. ESMO Open, 6(5), 100258. https://doi.org/10.1016/j.esmoop.2021.100258.
Zhang, H., & Chen, J. (2018). Current status and future directions of cancer immunotherapy. Journal of Cancer, 9(10), 1773–1781. https://doi.org/10.7150/jca.24577.
Zhang, J., Wang, S., Zhou, Z., Lei, C., Yu, H., Zeng, C., Xia, X., Qio, G., & Shi, Q. (2023). Unpleasant symptoms of immunotherapy for people with lung cancer: A mixed‐methods study. International Journal of Nursing Studies, 139, 104430. https://doi.org/10.1016/j.ijnurstu.2022.104430.
Zwanenburg, L., Suijkerbuijk, K., van Dongen, S., Koldenhof, J., van Roozendaal, A., van der Lee, M., & Schellekens, M. (2022). Living in the twilight zone: A qualitative study on the experiences of patients with advanced cancer obtaining long‐term response to immunotherapy or targeted therapy. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764‐022‐01306‐9.

7165318 Macmillan Cancer Support

Keywords: cancer; immune checkpoint inhibitors; patient experience; qualitative research; systematic review

0 (Immune Checkpoint Inhibitors)

Date Created: 20240409 Date Completed: 20240708 Latest Revision: 20240708

20240708

10.1111/jocn.17154

38589992